Navigation Links
Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference
Date:11/8/2011

ith the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The ADASUVE NDA will be presented to an advisory committee on December 12, 2011.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.  

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential, efficacy and safety of ADASUVE (Staccato loxapine). Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory appro
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... participate in the Deutsche Bank Health Care Conference to ... Hotel.  Mr. Adrian Adams , Chief ... overview of the Company and its product pipeline at ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The ...
(Date:5/24/2013)... May 24, 2013 The potential ... systemic delivery of therapeutic agents has been receiving undeniable ... delivery showing significant promise. The crucial formulation considerations for ... device play a major role in the efficiency of ... the development of new formulation techniques and devices in ...
(Date:5/23/2013)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) ... Life Science Firm of the Year by the Tech Council ... at the TCM,s 25 th Annual Tech Awards Celebration ... Awards Celebration recognizes the leaders and innovators in the technology ... and the surrounding regions. "We are deeply ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2
... 2011 With the support of Key Opinion Leaders ... the time and attention of KOLs is intensifying. But ... landscape for creating and maintaining KOL and physician relationships. ... KOL landscape, Best Practices, LLC has published an updated ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today ... of President, HealthTronics Inc., effective Aug. 29, 2011. HealthTronics, ... urological products and services based in Austin, Texas. ... HealthTronics Group President James Whittenburg, who is staying through ...
Cached Medicine Technology:Pharma Medical Science Liaison Outreach Shifting Away from Traditional Company Sales Regions 2Endo Pharmaceuticals Announces Leadership Change at HealthTronics Subsidiary: Appoints Kelly Huang, Ph.D. New President 2Endo Pharmaceuticals Announces Leadership Change at HealthTronics Subsidiary: Appoints Kelly Huang, Ph.D. New President 3
(Date:5/25/2013)... New York, NY (PRWEB) May 25, 2013 Country ... was Jason Aldean's opening act in 2012. Due to overwhelming ... countless venues during 2013. , Luke Bryan has written ... a songwriter nearly a decade ago back in the mid-2000 era. ... Billy Currington and Travis Tritt. , When Luke was 14, ...
(Date:5/25/2013)... 25, 2013 According to an article in ... a Feeling,” nearly 30 million Americans tan indoors each year ... despite knowing the health risks. New research suggests ... addictive effect on the brains of some tanners (Go to ... article so I can’t say that I fully support this ...
(Date:5/25/2013)... It's not astonishing that holidays are amongst the most ... from family, friends and co-workers. Between the parties to ... their parents can afford, parties to arrange, and so ... anniversaries and it seems like an eternal cycle of ... and income can’t catch up to the expenses of ...
(Date:5/25/2013)... May 25, 2013 Life science and ... used to detect and create a new substance with ... and are also known as biotechnology reagents. Such reagents ... and education. , This market is driven by factors ... the field of therapeutics, growth in research and rapid ...
(Date:5/25/2013)... New York, New York (PRWEB) May 25, 2013 ... a federal multidistrict litigation underway in U.S. District Court, ... Liebhard LLP reports. According to a Case Management ... procedures that govern the filing of contested motions in ... for filing those motions. (In re: Actos Product Liability ...
Breaking Medicine News(10 mins):Health News:Luke Bryan Tickets: Prices Slashed on Luke Bryan Tickets in Raleigh, Bethel, Camden, Peoria, Nashville, Hartford, Chicago, Boston, Atlanta, Indianapolis & SaratogaSprings 2Health News:Sun Damage – Are UV Rays Addictive? 2Health News:TheBeautyPlace.com Debuts Their Brand New Beauty Kits 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3
... 17 Carla Bluhm, a developmental psychologist and visiting assistant ... class of 2007, have recently completed a book on the ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080220/DC14623 ) , ... Identity and the New Science of Face Transplants" begins with ...
... for Physicians , , VOORHEES, ... infection (CDI) in geriatric and pediatric populations ... in CDI incidence in many age groups, healthcare professionals need ... patient populations. , , To ...
... Dec. 17 minSURG Corporation, along with,its ... NuFix,Inc. ("NuFix"), along with its affiliate Nutech ... settlement of the lawsuits styled Orthopedic,Development Corporation ... Inc., Kenneth Horton and Todd Gilbert, Case ...
... 17 Michelle Aguilar may be the latest,"Biggest Loser" but she ... that when working out hard, it,s important to include the nutrients ... a day provide.,Aguilar is the latest person to lend her upper ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081217/AQW560 ) , ...
... Labs announces the,availability of its advanced ocular nutrition line ... CVS Pharmacy stores ( www.cvs.com ),nationwide. , ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081217/CLW029-b ... marks the first time EyeScience Macular Health Formula(TM) and,EyeScience ...
... improve cognitive impairment, study says , , WEDNESDAY, Dec. ... Alzheimer,s patients, cognitive symptoms are also a safe ... such as aggression, wandering and paranoia, according to ... that examined the effectiveness of three popular cholinesterase ...
Cached Medicine News:Health News:Psychology of Face Transplants is Subject of New Book by Allegheny College Professor 2Health News:Current Concepts in Clostridium difficile Infection: A Focus on Geriatric and Pediatric Patients 2Health News:EyeScience's New Ocular Nutrition Supplements Available at CVS Stores 2Health News:Alzheimer's Drugs Also Treat Behavioral, Psych Problems 2
... a whole blood control for evaluating the ... measure automated blood cell counts in patient ... RBC and WBC values for the Abbott ... LH750/LH 755 (levels 2 and 3 only) ...
iSleep 20i is an advanced high performance CPAP with outstanding self-adjusting i‑technology....
Spectrum Dynamics empowers Nuclear Imaging with the SmartR Technology,of the D-SPECT Cardiac Imaging System. The D-SPECT is powered by BroadView Technology to provide unprecedented throughput, whil...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: